Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes
Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Edmund K. Waller(Emory University), Pierre Laneuville(McGill University Health Centre), Luciano J. Costa(University of Alabama at Birmingham), Michael A. Pulsipher(Primary Children's Hospital), Mitchell E. Horwitz(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Isabelle Bence‐Bruckler(University of Ottawa), Kazunobu Kato(Otsuka (United States)), Rosa F. Yeh(Seattle Cancer Care Alliance), Ira Braunschweig(The University of Texas MD Anderson Cancer Center), Damiano Rondelli(University of Illinois Chicago), James R. Mason(Sheba Medical Center), César O. Freytes(CHRISTUS Transplant Institute), Andy I. Chen(Scripps Research Institute), Weiyun Z. Ai(City College of San Francisco), Shin Mineishi(University of Alabama at Birmingham), Cong Xu(Otsuka (United States)), Tulio E. Rodriguez(Loyola University Medical Center), Tsiporah B. Shore(Cornell University), Jennifer Le‐Rademacher(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Michael Craig(Edith Cowan University), Marcelo C. Pasquini(Cleveland Clinic), Terrance Comeau, Yanlin Wang(Shanghai Jiao Tong University), Andrew M. Yeager(University of Arizona), Angela Smith(Otsuka (United States)), Thomas C. Shea(University of North Carolina at Chapel Hill), Joseph W. Fay(Sheba Medical Center), William P. Vaughan(University of Pennsylvania Health System), Ian W. Flinn(Tennessee Oncology), Philip J. Bierman(Susan Thompson Buffett Foundation), Michael Lill(Cedars-Sinai Medical Center)
Cited by 24
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k